Background: Recently, the Food and Drug Administration (FDA) proposed to expand the options for primary end points in the development of medications for alcohol use disorder to include either abstinence from alcohol or a nonabstinent outcome: no heavy drinking days (with a heavy drinking day defined as more than 3 drinks per day for women and more than 4 drinks per day for men [>3/>4 cutoff]). The FDA also suggested that 6 months would be the most appropriate length for a clinical trial to demonstrate the stability of this nonabstinent drinking outcome. However, few alcohol clinical trials have examined the stability of nonheavy drinking during and after treatment.
H EAVY DRINKING,DEFINED by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as more than 3 standard drinks (containing 14 g of pure alcohol) for women and more than 4 standard drinks for men, is common during and following treatment for alcohol use disorders (AUDs). For example, in the COMBINE study (Anton et al., 2006) , 70.9% of individuals across treatment groups experienced at least 1 heavy drinking day and 29.1% were stable nonheavy drinkers or abstainers during the 4 months of treatment, while during the 12 months following treatment, more than 80% experienced at least 1 heavy drinking day and fewer than 20% were stable nonheavy drinkers or abstainers. A marker of AUD treatment success, percent subjects with no heavy drinking days, has been recommended by the Food and Drug Administration (FDA) as an acceptable alternative to complete abstinence as a primary end point for Phase III alcohol clinical trials (Falk et al., 2010; FDA, 2015) . An emerging body of literature supports the validity of no heavy drinking as a useful surrogate for clinically meaningful benefit. For example, studies have examined no heavy drinking days as an efficacy end point (Falk et al., 2010) and demonstrated an association between no heavy drinking and longterm outcomes (Kline-Simon et al., 2013) .
The FDA currently conceptualizes "no heavy drinking" (i.e., either abstinence or low-risk drinking [i.e., drinking below the >3/>4 definition]) throughout a clinical trial as indicative of treatment success. However, recent research has shown that heavy drinkers are heterogeneous in their posttreatment psychosocial functioning and that some treatment "failures" who engage in limited heavy drinking report psychosocial functioning that is similar to individuals with abstinent or nonheavy drinking outcomes during treatment Witkiewitz et al., 2017a,b) . The FDA guidance also recommends a trial length of at least 6 months (FDA, 2015) to ensure the stability of the observed outcomes. In the COMBINE study, which was a 4-month treatment period, responder analyses suggested that individuals with some heavy drinking days may still have had a positive treatment response to naltrexone, that is, that they had fewer heavy drinking days than those who received placebo medication . Thus, an analysis of the patterns of heavy drinking in alcohol clinical trial participants is critical to determine whether, when, and to what degree heavy drinking stabilizes as persistent heavy drinking or as stable nonheavy drinking.
The aims of the current study were 3-fold: (i) to gain a better understanding of the rates and stability of heavy drinking among individuals with AUD enrolled in the COMBINE study (Anton et al., 2006) across 3 different clinically relevant time frames: during treatment (months 1 to 4), the transition from receiving treatment to not receiving treatment (months 4 to 7), and the last 4 months of the 1-year followup (months 13 to 16); (ii) to determine whether individuals with heavy drinking days have similar drinking outcomes (e.g., percent drinking days [PDD] , drinks per drinking day [DDD] ) during treatment; and (iii) to assess changes in drinking from baseline to the end of treatment among individuals who are considered treatment nonresponders, that is, they had at least 1 heavy drinking day.
MATERIALS AND METHODS

Participants and Procedures
As described elsewhere (Anton et al., 2006) , the COMBINE study ("Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence"; COMBINE Study Group, 2003) randomized 1,383 subjects from 11 research sites into 9 treatment groups, consisting of a combination of medical management (MM) or combined behavioral intervention (CBI) and medications (acamprosate, naltrexone, or placebo versions of each drug). Subjects received treatment for a total of 16 weeks; participants were offered 9 MM visits and a maximum of 20 CBI sessions. They completed assessments at 10, 36, and 52 weeks following treatment. In this study, patients from all treatment modalities were included in the analyses because we were interested in patterns and stability of drinking changes during treatment, regardless of treatment assignment. Sensitivity analyses were conducted in which the naltrexone (n = 614) and the CBI (n = 619) groups, which received treatments that were effective in the primary analyses (Anton et al., 2006) , were excluded. Exclusion of the naltrexone or CBI groups did not greatly alter the conclusions; thus, the results from all treatment groups are described below in detail; the results with naltrexone or CBI excluded are available from the first author.
The sample was recruited from treatment referrals at the study sites and advertising in the community. Key inclusion criteria included a diagnosis of alcohol dependence based on the DSM-IV (American Psychiatric Association, 1994), age 18 years or older, abstinence from alcohol at least 4 days prior to randomization, a minimum weekly average of 14 drinks (females) or 21 drinks (males) over a successive 30 days in the 90-day period prior to initiating abstinence, and at least 2 days of heavy drinking (defined as 4+ drinks for females and 5+ drinks for males) in the 90-day period, with the last drink within 21 days of enrollment. Individuals were excluded if they (i) were dependent on a drug other than alcohol, nicotine, or cannabis, (ii) recently used opioids, (iii) had a serious mental illness, (iv) had any other medical condition that could disrupt study participation, (v) had taken 1 of the study medications during the 30 days prior to baseline, or (6) took medication that could increase the potential risks of the study.
Of the 1,383 participants in COMBINE, 31% were female and 69% were male and nearly a quarter were racial/ethnic minorities (76.3% non-Hispanic White, 11.6% Hispanic American, 7.8% African American, and 4.1% "other"). The participants' mean age was 44.4 years (SD = 10.2), 71% had at least 12 years of education, and 42% were married. Complete drinking data were available from 94% of all participants during treatment (see missing data handling below). At baseline, participants in COMBINE were drinking on 78.6% of days (SD = 22.5%), with most of these days considered heavy drinking days (mean = 67.8%; SD = 28.0%), and an average of 11.0 drinks per drinking day (SD = 6.8).
Measures
The occurrence of 1 or more heavy drinking days versus no heavy drinking days by month was our primary binary outcome variable. Alcohol consumption was assessed using a calendar method with the Form 90 Interview (Miller, 1996) . Daily alcohol consumption was assessed monthly during treatment and at assessments conducted at 10, 36, and 52 weeks following treatment. Heavy drinking days were defined as days on which participants drank more than 4 standard drinks ("4+") for women and more than 5 standard drinks ("5+") for men, using the NIAAA definition of a standard drink (one that contains 14 grams of alcohol). Although the FDA and NIAAA define heavy drinking as more than 3 drinks for women (">3") and more than 4 drinks per men (">4"), we defined heavy drinking by the whole drink equivalents of 4 or more for women and 5 or more for men, which is consistent with many clinical trials (Maisto et al., 2016 ; National Institute on Alcohol Abuse and Alcoholism, 2005 ). An inspection of the standard drinks consumed on a random sample of days during each month indicated that <3% of the COMBINE sample consumed between 3 and 4 standard drinks among women or between 4 and 5 standard drinks among men. Thus, the results using the 4+/5+ definition in this study would be expected to be similar to those obtained had the >3/>4 cutoffs been used.
Each month in which a heavy drinking day occurred was coded as positive (1); each month with no heavy drinking days was coded as negative (0). We examined 3 four-month time periods: during treatment (months 1 to 4), the transition from in-treatment (month 4) to posttreatment (months 5 to 7), and during the last 4 months of the 1-year posttreatment follow-up (months 13 to 16). These 4-month periods were examined because the treatment duration was 4 months, and we wished to use periods of equivalent duration during the transition out of treatment and at follow-up. Also, the models to be estimated, described below, could not accommodate the full duration of the period from months 1 to 16 and thus we estimated the models in 4-month periods.
We then computed secondary drinking outcome measures defined by frequency (PDD) and intensity of drinking (DDD), among individuals who had at least 1 heavy drinking day. These enabled us to characterize the frequency and intensity of drinking being reported among individuals who would be considered treatment failures because they had at least 1 heavy drinking day in a given month.
Statistical Analyses
A combination of descriptive and inferential analyses was used to examine stability and change in the occurrence of heavy drinking across time in COMBINE. Descriptive analyses using frequencies and crosstabs were conducted to determine the observed monthly prevalence of heavy drinking and no heavy drinking during each period. A Cohen's kappa statistic (Cohen, 1960) was calculated to assess the degree of stability (i.e., chance-corrected agreement) in observed heavy drinking and no heavy drinking across time, where kappa = 0 would indicate no stability in the observed drinking status across time and kappa = 1 would indicate perfect stability in the observed drinking status from 1 month to the next month. Kappa represents chance-corrected agreement, with a value >0.61 defined as substantial agreement (i.e., stability in this case) and kappa >0.81 defined as nearly perfect agreement (Landis and Koch, 1977) . At this descriptive stage, we used observed data without imputing missing values.
The aims of inferential analyses were (i) to gain a better understanding of the patterns of heavy drinking among individuals with AUD; (ii) to determine whether those with heavy drinking days are homogeneous (i.e., come from the same population) or heterogeneous in terms of their drinking outcomes (e.g., PDD, DDD) during treatment; and (iii) to assess the degree of drinking changes from baseline to the end of treatment among individuals with 1 or more heavy drinking days.
Latent variable mixture modeling was the primary analysis technique for all models. Mixture modeling is a useful tool for accommodating nonnormality of drinking outcomes at a given time point and discontinuous changes in drinking over time (Lanza and Collins, 2006; Muth en and Muth en, 2000; Witkiewitz et al., 2010) by estimating a nonnormal distribution with a certain number of separate distributions (i.e., latent classes), which are hypothesized to be meaningful subpopulations of individuals with similar outcomes. Model building and selection were based on prior research, theoretical considerations, and empirical indices of model fit. All models were estimated using Mplus version 7.3 (Muth en and Muth en, 2012) using maximum-likelihood estimation with robust estimation of standard errors (Yuan and Bentler, 2010 ) and a logit link function. Missing data were accommodated via maximum-likelihood estimation procedures, which provide an estimate of the variancecovariance matrix given all available data. Maximum-likelihood estimation is an effective approach for handling data that are missing at random (Enders, 2010; Graham, 2009; Hallgren and Witkiewitz, 2013; Witkiewitz et al., 2014) . Models with differing numbers of classes across models were compared using the Bayesian information criterion (BIC; Schwarz, 1978) , a preferred index for determining the number of classes in longitudinal mixture models (Nylund et al., 2007) . The model with the lowest BIC within a group of comparison models was selected. An entropy statistic, which reflects the probability of accurate classification within latent classes from 0.0 (0% accurate) to 1.00 (100% accurate), was examined to evaluate classification precision.
Transitions in Heavy Drinking: Latent Markov Models of Heavy Drinking Days
To gain a better understanding of the rates and patterns of heavy drinking among individuals with AUD enrolled in the COMBINE study across 3 different clinically relevant time frames, we used latent Markov models (LMMs) to examine the probability of transitioning between latent classes across time (months during each period). LMMs can be used to examine a finite number of unobserved (i.e., latent) states and the probabilities of remaining in the same latent state or shifting to a different latent state across time (B€ ockenholt, 2005) . LMMs were used to estimate the probability of heavy drinking during the next month, given heavy drinking or nonheavy drinking during the prior month, as well as the probability of stability and change in heavy drinking across months in each time period. Ultimately, we were most interested in the rates of transitioning (indexed by the transitional probabilities [s parameters)]) between latent heavy drinking and nonheavy drinking classes.
We estimated 3 sets of models for each data set: during treatment (occurrence of heavy drinking days across the 4 months of treatment in COMBINE), transition out of treatment (occurrence of heavy drinking days across the last month of treatment [month 4] and 3 months following treatment [months 5 to 7] in COMBINE), and following treatment (occurrence of heavy drinking days over the past 4 months at the 12-month follow-up in COMBINE). For each set of models, we found that the models with 2 latent classes per time point, described in detail for each time period below, provided a better fit based on lower BIC than models with 3, 4, or 5 latent classes, and the classification precision (entropy) was also highest for the 2-class model. For example, during treatment, the BIC of the 2-class model was 5,668.4 and BIC increased with each additional class (3-class BIC = 5,759.3; 4-class BIC = 5,902.0; 5-class BIC = 6,089). Entropy was 0.83 for the 2-class model (indicating acceptable classification precision; Nylund et al., 2007) and decreased with each additional class (3-class entropy = 0.781; 4-class entropy = 0.712; 5-class entropy = 0.647).
Model difference testing across alternative nested models was conducted using the Satorra-Bentler scaled chi-square difference test. Specifically, we conducted tests of invariance across time for 2 parameters of the LMM: the measurement parameters (q), which index the probability of heavy drinking conditional on latent class membership at each time point; and the transition probabilities (s), which index the probability of expected class membership at time t + 1 given expected class membership at time t. For all models, described below, the scaled chi-square difference test indicated that the measurement parameters (q) could be constrained to be invariant across time without sacrificing model fit (all ps > 0.06), such that latent states at each time point could be constrained to be equivalent. The models did differ on the invariance of the s parameters, as reported in detail below. Based on prior work (Witkiewitz, 2008; Witkiewitz et al., 2010) , we hypothesized that the probability of transitioning would be greatest during treatment and in the months following treatment, whereas the rates of transitioning would decrease at the 12-month follow-up when heavy drinking (or nonheavy drinking) states may become more stable. Covariates and treatment group were not considered in the analyses because we were most interested in studying the patterns of stability and change in heavy drinking across time, irrespective of treatment and other covariates. Sensitivity analyses conducted with demographic variables (e.g., sex, race, education) and treatment group included as covariates showed that none of the results changed substantively when covariates were included.
Homogeneity of Heavy Drinking Population: Latent Profile Models of Drinking Frequency and Intensity (PDD and DDD) Among Heavy Drinkers During Treatment
Latent profile models were used to examine contemporaneous drinking outcomes (PDD and DDD) among individuals who engaged in heavy drinking during each month of treatment. Specifically, the PDD and DDD variables were used as indicators in latent profile models (analogous to a latent class analysis) during treatment. The same process of model testing was conducted with the BIC, entropy, the Lo-Mendell-Rubin (LMR) likelihood ratio test, and the substantive interpretation of latent classes as the primary methods to select the final model within each month. The LMR, which provides a statistical test of the improvement in model fit by each additional class, was used to test the null hypothesis that individuals who engaged in at least some heavy drinking come from a single population (i.e., a 1-class model provides the best fit to the data) and were homogeneous with respect to their drinking outcomes. Specifically, we used the LMR test to compare models with an increasing number of latent classes, with each latent class theoretically characterizing different subpopulations of average PDD and DDD. If the LMR rejected the 1-class solution, then alternative class solutions were examined using the BIC and LMR to identify the number of latent classes within each treatment month. The LMR test is available for mixture models with only 1 latent class variable (e.g., the latent profile model) and is not available when there is more than 1 latent class variable (e.g., the LMM); thus, the LMR test was used only to compare latent profile models and not to estimate the LMMs. Assuming heterogeneity of the latent classes, we compared the baseline PDD and DDD among individuals who were most likely classified in each of the latent classes using the latent profile model from the end of treatment (month 4). The goal of this analysis was to evaluate how individuals changed their drinking from baseline to the end of the treatment period based on latent drinking class membership during the last month of treatment. Mean differences in baseline PDD and DDD were estimated using a model-based approach (the BCH method; Asparouhov and Muth en, 2014) in which the average class-specific means of the baseline PDD and DDD variables were estimated with classification error of the model taken into account in estimating the weighted means by latent class membership in the end of treatment latent profile model.
RESULTS
Descriptive Statistics
The observed (nonimputed) prevalence of heavy drinking in a given month in the sample was consistent across the 16 months, averaging 51.7% (SE = 1.51%; Table 1 ). The observed cumulative prevalence of any heavy drinking, also shown in Table 1 , increased over time with the largest increases in cumulative number of any heavy drinking occurring during the first 3 months of treatment. Specifically, as shown in the third column of Table 1 , across the entire 16-month period, 1,113 (85.3%) individuals in the COMBINE sample engaged in any heavy drinking and 897 (66.7%) engaged in heavy drinking by month 3. In other words, 80.6% of those who ever engaged in heavy drinking (i.e., 897/1,113) across the entire 16-month period engaged in heavy drinking by month 3.
The observed associations of nonimputed heavy drinking between consecutive months across the 16-month follow-up period are shown in Table 2 . For example, 84.1% of subjects who reported heavy drinking during the first month of treatment also reported heavy drinking during the second month, whereas 15.9% of the sample reported initial heavy drinking followed by no heavy drinking. Similarly, 76.7% of subjects reporting no heavy drinking in month 1 remained in that category during month 2, whereas 23.3% were engaging in heavy drinking in month 2. In general, as indicated by the estimates of kappa reported in Table 2 , the agreement for heavy drinking was substantial (>0.64) in consecutive months and increased over time to a maximum of kappa = 0.78 from months 11 to 12, suggesting an increasing stability of the no heavy drinking outcome.
Transitions in Heavy Drinking: LMMs of Heavy Drinking Days
During Treatment (Months 1 to 4). As noted above, the model with 2 latent classes per time point provided a better fit than models with 3, 4, or 5 latent classes, and the classification precision (entropy) was also highest for the 2-class model. The 2 latent classes could best be described as 1 class with a high probability of no heavy drinking (probability of no heavy drinking = 0.935) and a second latent class characterized by a high probability of at least some heavy drinking (probability of heavy drinking = 0.940). The class prevalence changed over time with expected classification (based on estimated posterior probabilities) of membership in the no heavy drinking class of 52.3% at month 1, 47.8% at month 2, 49.1% at month 3, and 51.7% at month 4. Note that these results are consistent with the observed categories shown in Table 1 , with slight differences due to modeling of probabilities of heavy drinking and no heavy drinking.
Second, we examined whether we could assume measurement invariance of the transition probabilities (s) across months 1 to 4. The model with s parameters constrained to All numbers are observed (percentages are based on valid number of cases) with no imputation for missing data. equality across months 1 to 4 fit significantly worse (scaled chi-square difference (Ddf) = 15.00 (4), p = 0.005) than the less restricted model with s parameters allowed to vary across months 1 to 4, supporting changing transitional probabilities during treatment. Consistent with the descriptive results, the probability of transitioning from nonheavy drinking to heavy drinking decreased over time, with the greatest probability (p) = 0.143 in month 1 to month 2, followed by p = 0.083 in month 2 to month 3, and p = 0.066 in month 3 to month 4. In contrast, the probability of transitioning from heavy drinking to nonheavy drinking increased over time during treatment, with p = 0.063 from months 1 to 2, p = 0.100 from months 2 to 3, and p = 0.114 from months 3 to 4.
Transition Out of Treatment (Months 4 to 7)
. Again, the model with 2 latent classes per time point provided a better fit (i.e., had a lower BIC) than 3-, 4-, or 5-class models. The 2 latent classes could be characterized by 1 latent class with a high probability of no heavy drinking (probability of no heavy drinking = 0.944) and a second latent class characterized by a high probability of at least some heavy drinking (probability of heavy drinking = 0.966).
The model s parameters constrained to equality across months 4 to 7 did not fit significantly worse than the less restricted model with s parameters allowed to vary across months 4 to 7 (scaled chi-square difference (Ddf) = 2.84 (4), p = 0.58), supporting measurement invariance of s parameters across months 4 to 7. This indicates that the transitions between nonheavy and heavy drinking over time could be constrained to be equal over time without a significant decrement in overall model fit. The latent transition probabilities (which were constrained to be equal over time) showed considerable stability, with a 0.917 probability of remaining classified in the non-heavy drinking class across consecutive months and a 0.941 probability of remaining classified in the heavy drinking class across consecutive months.
12 Months Following Treatment (Months 13 to 16). The BIC was lowest and the entropy statistic was highest for the 2-class model. The 2 latent classes could best be described as 1 class with a high probability of no heavy drinking (probability of no heavy drinking = 0.956) and a second latent class characterized by a high probability of at least some heavy drinking (probability of heavy drinking = 0.979).
The model with s parameters constrained to equality across months 13 to 16 did not fit significantly worse (scaled chi-square difference (Ddf) = 5.03 (4), p = 0.28) than the less restricted model with s parameters allowed to vary across months 13 to 16, again supporting measurement invariance of s parameters across time. The latent transition probabilities indicated considerable stability, with a 0.971 probability of remaining classified in the nonheavy drinking class across consecutive months and a 0.947 probability of remaining classified in the heavy drinking class across consecutive months.
Homogeneity of Heavy Drinking Population: Latent Profile Models of Drinking Frequency and Intensity (PDD and DDD) Among Heavy Drinkers During Treatment
The second set of analyses examined drinking frequency (PDD) and intensity (DDD) among subjects with a heavy drinking day in a given month. The results of the LMR likelihood ratio test for the latent profile models for each month showed that 2 to 3 latent classes generally provided the best fit during treatment. Importantly, the LMR rejected the 1-class model for all months of treatment (all p < 0.001; showing that individuals who engage in heavy drinking come from more than a single population and can thus be described by at least 2 classes). For all models, the BIC tended to decrease with each additional latent class and the entropy statistic indicated good classification precision across all models. Given substantive interpretation of the resulting class solutions and prior research (Witkiewitz, 2008; Witkiewitz et al., 2010) , we selected the models with 3 latent classes as the final model within each month of treatment. The probabilities of class membership (expressed as the percentage of heavy drinkers within each class) and average PDD and DDD within each class by month are shown in Table 3 . The largest class, Class 1 (which we labeled "moderate intensity, occasional drinking"), had an estimated probability of class membership ranging from 0.691 (month 1) to 0.617 (month 4), thus representing more than two-thirds (61.7% to 69.1%) of the sample. Individuals with expected classification in Class 1 drank, on average, 6 DDD on approximately 24% of days in a month (i.e., 7 days per month). The second largest class, Class 2 (which we labeled as "moderate intensity, frequent drinking"), had an estimated probability of class membership ranging from 0.268 (month 1) to 0.364 (month 4) and drank, on average, 6 to 7 DDD on approximately 79% to 84% of days in a month (24 to 25 days per month). The smallest class, Class 3 (which we labeled as "high intensity, variable frequency"), had an estimated probability of class membership ranging from 0.018 (month 4) to 0.047 (month 2), representing a minority (1.8% to 4.7%) of the sample. This class had very high drinking intensity, with average DDD ranging from 21.1 (month 1) to 28.2 (month 4), and variable drinking frequency, with PDD ranging from 24.6% (month 1) to 77.4% (month 3).
Drinking Reductions from Baseline to the End of Treatment (Month 4) Among Heavy Drinkers
The average PDD and DDD at baseline by the month 4 latent classes, shown in Fig. 1 , indicated that Class 2 (moderate intensity, frequent drinking) heavy drinkers had significantly higher PDD at baseline than either Class 1 heavy drinkers (moderate intensity, occasional drinking; Wald v Class 1 (moderate intensity, occasional drinking) showed the most improvement of the 3 classes with a 64% reduction in the frequency of drinking (from 68.0% at baseline to 24.3% at month 4) and a 38% reduction in DDD (from 11.0 drinks at baseline to 6.8 drinks at month 4) from baseline to the end of treatment. Class 2 (moderate intensity, frequent drinking) had only a 1.1% reduction in the frequency of drinking, but reduced DDD by 25% from baseline to the end of treatment. Class 3 (high intensity, variable frequency) showed some improvement in drinking frequency with a 33% reduction in PDD but a 10% increase in DDD from baseline to the end of treatment. 
DISCUSSION
We used data from a large multisite clinical trial for AUD to investigate the rates and transitions in heavy drinking among patients with AUD across 3 clinically relevant timeframes: during treatment, in the transition period from treatment to posttreatment, and in the last 4 months of the year following treatment. The Markov modeling approach used in the present study allowed us to examine individual transitions from month-to-month. As hypothesized, rates of heavy drinking days showed increasing stability over time, with most transitions into or out of heavy drinking occurring during treatment. After the 4-month treatment period of COM-BINE, the probability of changes in heavy drinking status (reported in Table 2 ) across consecutive months decreased by almost half, from 16.3% in months 4 to 5 to 9.4% in months 15 to 16.
Further, we sought to determine whether individuals with heavy drinking days could be considered a homogeneous group in terms of their drinking outcomes. Findings from the latent profile models indicated that a 1-class solution (indicating a homogeneous population) was rejected during each month of treatment, indicating heterogeneity in drinking among the heavy drinking patients and suggesting heavy drinkers are not necessarily a uniform group of treatment nonresponders. The vast majority of heavy drinkers at the end of treatment had large reductions in drinking intensity or frequency (or both) from baseline levels. Over 60% of these heavy drinkers were classified as moderate intensity, occasional drinkers (Class 1, Fig. 1 ) reporting, on average, a 64% reduction in drinking frequency (PDD) and a 38% reduction in drinking intensity (DDD) from baseline. Over one-third of these heavy drinkers were classified as moderate intensity, frequent drinkers (Class 2, Fig. 1 ) reporting, on average, a 25% reduction in drinking intensity with no change in drinking frequency from baseline. Finally, a small percentage of heavy drinkers (approximately 1.8%) were classified as high intensity, variable frequency drinkers (Class 3, Fig. 1 ) reporting, on average, a 33% reduction in drinking frequency with a small increase in drinking intensity. Overall, the notion that some heavy drinkers might have clinically meaningful reductions in heavy drinking, as compared to baseline levels, is consistent with recent work demonstrating heterogeneity in psychosocial functioning among heavy drinkers, such that the majority of heavy drinkers with AUD who receive treatment in alcohol clinical trials exhibit psychosocial functioning similar to abstainers and light drinkers following treatment Witkiewitz et al., 2017b) . This finding has important clinical implications for a harm reduction approach to AUD.
The present study can be viewed as providing a high-definition view of the temporal stability of drinking behavior from month-to-month during treatment, which has previously been assessed in different epidemiological and clinical samples over 7 years (Delucchi and Weisner, 2010 ) and 3 years (Dawson et al., 2007) . Consistent with these prior findings, our analyses showed increasing stability in drinking patterns, but are the first to highlight the relative stability of drinking behavior across 4 months of treatment, which has important research and clinical implications. Most prior longitudinal studies of alcohol treatment outcomes have examined drinking behavior defined by continuous change in alcohol use (e.g., for a review see Maisto et al., 2014) ; however, this approach fails to acknowledge discontinuous change in alcohol use from month-to-month, including the important transitions from no heavy drinking to heavy drinking and vice versa. The FDA has suggested that studies supporting the use of a medication for alcohol treatment be at least 6 months in duration (FDA, 2015) , based partially on the need for the stability of observed drinking reports. Our results provide evidence of marked stability from month-to-month in drinking outcome using the "any heavy drinking" definition during 4 months of treatment, the length of the COMBINE study. Clinically, the results suggest that individuals who are doing well during the first 3 months of treatment have a lower probability of shifting to a heavy drinking outcome. Consistent with other recent analyses of alcohol clinical trial data (Witkiewitz et al., 2017a, b) , very high intensity heavy drinking during treatment (as observed in Class 3) might indicate a need to shift strategies or refer the patient to a higher level of care, clearly an indication of treatment failure.
The present study benefited from a large number of participants across 11 sites nationwide and analyses using both basic descriptive and advanced modeling approaches. One of the primary limitations of the present study was the inability to evaluate whether drinking remains stable over a longer trial (i.e., a 6-month trial, which is currently the FDA-recommended length for alcohol clinical trials). An additional limitation was the decision to use 4+/5+ definition of heavy drinking that is commonly employed in clinical trials, rather than the >3/>4 definition provided by the NIAAA and the FDA or additional alternative end points. There were few subjects (<3%) who were misclassified as nonheavy drinkers using this approach and including these individuals (who were drinking below the 4/5 cutoff, but above the >3/>4 cutoff) as heavy drinkers is unlikely to have a meaningful impact on the results. It is also important to note that most specialty treatment programs in the United States remain abstinence based. In our analysis of treatment success, abstainers and nonheavy drinkers were considered as 1 group. Thus it is unclear how the pattern of results might be different if we considered abstinence as the only marker for success. Because of the complexity of the analyses, it was not feasible to include an examination of an abstinence outcome in this article. It is also unclear whether the findings from the current study would generalize to a treatment that explicitly supports nonabstinence goals and provides training in controlled drinking. For example, selection of a nonabstinence goal in treatment has been associated with greater likelihood of nonheavy drinking, whereas those with abstinence goals in the same treatment were more likely to engage in heavy drinking when drinking occurred (Adamson et al., 2010) . Finally, the COMBINE study excluded individuals with severe psychiatric disorders and those with comorbid drug dependence (aside from nicotine); thus, the current results may not generalize to individuals with comorbid psychiatric or substance use disorder diagnoses.
Overall, the findings from this study suggest that clinicians and researchers may be able to assess the efficacy of a given treatment after an initial 2-to 3-month period using no heavy drinking days as a primary outcome, given that most change in heavy drinking occurs within the first 3 months. Additionally, these findings indicate that there are substantial reductions in drinking from baseline among individuals that we have traditionally labeled as treatment nonresponders, based on the no heavy drinking responder definition. The notion that individuals can move in and out of heavy drinking and be functioning quite well is consistent with epidemiological data (Dawson et al., 2007; Delucchi and Weisner, 2010) and recent studies in AUD samples Witkiewitz et al., 2017a,b) . On average, the majority of patients (those in Class 1) show considerable improvements in the frequency and quantity of alcohol consumed during and after treatment, despite being categorized as nonresponders by virtue of having had at least 1 heavy drinking day in a specific period during the clinical trial. This finding suggests that other end points need to be considered to evaluate the impact of alcohol treatment. These end points could include other conceptualizations of drinking reduction (Hasin et al., in press; Witkiewitz et al., 2017a,b) , as well as reductions in nonconsumption outcomes (e.g., alcohol-related consequences, quality of life, physical/mental health). Importantly, future work should particularly seek to validate new drinking end points by demonstrating that improvement on these end points correlates with improvement on other clinically meaningful outcomes of health and social consequences. 
